Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New leukemia treatment offers hope

23.09.2016

Antibodies directed against cancer stem cells could help patients with acute myeloid leukemia.

An antibody drug that targets a surface marker on cancer stem cells could offer a promising new therapeutic approach for treating acute myeloid leukemia (AML), a form of blood cancer that affects an estimated 50,000 people in Saudi Arabia.


Antibodies that block CD44 could help destroy acute myeloid leukemia cells. © 2016 KAUST

The leukemia stem cells responsible for propagating the disease express a protein on their surface called CD44. Antibodies that block CD44 have been shown to trigger the stem cells to mature, leading to a reduction in the growth and proliferation of these stubbornly hard-to-treat cells. But it wasn’t clear how or why this happens.

Jasmeen Merzaban and her colleagues from King Abdullah University of Science and Technology (KAUST), Saudi Arabia, studied the signaling pathways that change through treatment with a CD44-directed antibody [1]. Working with both human AML cell lines and a mouse model, the researchers showed that inhibiting CD44 with the antibody led to a decrease in the expression of two central pathways implicated in the aberrant growth of cancer cells: the PI3K (phosphoinositide 3-kinase) and the mTOR (mammalian target of rapamycin) pathways.

Notably, the antibody blocked both of the structurally distinct complexes that include mTOR. That’s important because a complete shutdown of mTOR signaling is probably needed to disrupt the multiple feedback loops that can fuel cancer growth, and drugs that only inhibit one of these complexes have in the past, failed to demonstrate a therapeutic benefit for patients with AML.

“A growing body of evidence suggests that a broader inhibitor would result in a more potent therapeutic effect,” said Merzaban.

An anti-CD44 drug like the one tested by Merzaban might just be that broad inhibitor. Encouragingly, in her team’s hands it doesn’t seem to have toxicity issues.

“We show that the anti-CD44 antibody used for our studies had no effect on normal blood cells,” said Samah Gadhoum, a research scientist in Merzaban’s lab group at KAUST and the first author of the study. “However, more work is needed to carefully determine the effect of these antibodies on other cells and other cellular functions within the body.”

Merzaban, Gadhoum and their colleagues are now running follow-up experiments. For now, though, all their results “support the use of anti-CD44 antibodies for the treatment of AML as a differentiation-inducing therapy,” said Merzaban.

As an added bonus: Unlike other therapies that seem to work only for certain forms of the disease, “the interesting thing about CD44-antibody treatment is that it is able to induce differentiation of many more AML subtypes,” said Merzaban.

Associated links

Journal information

[1] Gadhoum, S.Z., Madhoun, N.Y., Abuelela, A.F. & Merzaban, J.S. Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: A new rationale supporting CD44-induced AML differentiation therapy. Leukemia advance online publication 8 August 2016 (doi: 10.1038/leu.2016.221).

Michelle D'Antoni | Research SEA
Further information:
http://www.researchsea.com

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

A new dead zone in the Indian Ocean could impact future marine nutrient balance

06.12.2016 | Earth Sciences

Significantly more productivity in USP lasers

06.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>